Abstract
Despite the advancements in diagnosis and therapy for hepatocellular carcinoma (HCC) that currently permit to treat with tailored strategies the disease in early stages, for intermediate and advanced stages the therapeutic options are far from optimal. In recent years, new targets have been searched by exploring the molecular pathways involved in hepatocarcinogenesis, leading to multiple trials on new agents interfering in these mechanisms.
In this article we revised the principal agents that raised major interest, from the one already established as gold standard for advanced HCC (sorafenib) to the new molecules still in preclinical or early clinical studies. The extensive investigation on the field will identify the best agents and the subsets of patients that will benefit most from their application.
Keywords: Hepatocellular carcinoma, kinase inhibitors, molecular therapy, signal pathways, treatment, Sorafenib, Organ- Specific Drug, Bevacizumab, Vatalanib, Sunitinb, Cediranib, SU6668, Dovitinib, Brivanib, ABT 869, Cetuximab, Gefitinib, Erlotinib, Lapatinib, ABT-100, Rapamycin, Everolimus, VEGF, TGF, EGF, IGFs, FGF, HGF
Current Signal Transduction Therapy
Title: New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Volume: 6 Issue: 2
Author(s): Fabio Farinati, Nora Cazzagon, Anna Giacomin and Anna
Affiliation:
Keywords: Hepatocellular carcinoma, kinase inhibitors, molecular therapy, signal pathways, treatment, Sorafenib, Organ- Specific Drug, Bevacizumab, Vatalanib, Sunitinb, Cediranib, SU6668, Dovitinib, Brivanib, ABT 869, Cetuximab, Gefitinib, Erlotinib, Lapatinib, ABT-100, Rapamycin, Everolimus, VEGF, TGF, EGF, IGFs, FGF, HGF
Abstract: Despite the advancements in diagnosis and therapy for hepatocellular carcinoma (HCC) that currently permit to treat with tailored strategies the disease in early stages, for intermediate and advanced stages the therapeutic options are far from optimal. In recent years, new targets have been searched by exploring the molecular pathways involved in hepatocarcinogenesis, leading to multiple trials on new agents interfering in these mechanisms.
In this article we revised the principal agents that raised major interest, from the one already established as gold standard for advanced HCC (sorafenib) to the new molecules still in preclinical or early clinical studies. The extensive investigation on the field will identify the best agents and the subsets of patients that will benefit most from their application.
Export Options
About this article
Cite this article as:
Farinati Fabio, Cazzagon Nora, Giacomin Anna and Anna , New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795660034
DOI https://dx.doi.org/10.2174/157436211795660034 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Cellulitis-Like Sweet Syndrome Preceding Multiple Myeloma. A Case Report
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Characterization of Cepharanthin Nanosuspensions and Evaluation of Their In Vitro Activity for the HepG2 Hepatocellular Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry An Updated Review of Natural Products Intended to Prevent or Treat Oral Mucositis in Patients Undergoing Radio-Chemotherapy
Current Pharmaceutical Biotechnology Editorial
Recent Patents on Anti-Cancer Drug Discovery Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Targeted Therapies in Hepatocellular Carcinoma
Current Medicinal Chemistry Molecular Docking Analysis of Flavonoid Compounds with Matrix Metalloproteinase- 8 for the Identification of Potential Effective Inhibitors
Letters in Drug Design & Discovery Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation
Current HIV Research Expression of Fucosyltransferases Contributes to Melanoma Invasive Phenotype
Medicinal Chemistry MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Current Medicinal Chemistry Targeting HER Receptors in Cancer
Current Pharmaceutical Design Association of EGF rs4444903 and XPD rs13181 Polymorphisms with Cutaneous Melanoma in Caucasians
Medicinal Chemistry Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
Current Pediatric Reviews Role of Epigenetics and Oxidative Stress in Gliomagenesis
CNS & Neurological Disorders - Drug Targets Biological Activities of Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets